Evaluation of antitumor activity of a TGF-beta receptor I inhibitor (SD-208) on human colon adenocarcinoma.
Daru
; 22: 47, 2014 Jun 05.
Article
em En
| MEDLINE
| ID: mdl-24902843
ABSTRACT
BACKGROUND:
Transforming growth factor-ß (TGF-ß) pathway is involved in primary tumor progression and in promoting metastasis in a considerable proportion of human cancers such as colorectal cancer (CRC). Therefore, blockage of TGF-ß pathway signaling via an inhibitor could be a valuable tool in CRC treatment.METHODS:
To evaluate the efficacy of systemic targeting of the TGF-ß pathway for therapeutic effects on CRC, we investigated the effects of a TGßRI (TGF-ß receptor 1) or TßRI kinase inhibitor, SD-208, on SW-48, colon adenocarcinoma cells. In this work, in vitro cell proliferation was studied by methyl thiazolyl tetrazolium (MTT) and bromo-2'-deoxyuridine (BrdU) assays. Also, the histopathological and immunohistochemical evaluations were conducted by hematoxylin and eosin, and Ki-67 and CD34 markers were stained, respectively.RESULTS:
Our results showed no significant reduction in cell proliferation and vessel formation (170 ± 70 and 165 ± 70, P > 0.05) in treated SW-48 cells with SD-208 compared to controls.CONCLUSION:
Our data suggested that SD-208 could not significantly reduce tumor growth and angiogenesis in human colorectal cancer model at least using SW-48 cells.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Pteridinas
/
Adenocarcinoma
/
Fator de Crescimento Transformador beta
/
Neoplasias do Colo
/
Antineoplásicos
Tipo de estudo:
Prognostic_studies
Limite:
Animals
/
Female
/
Humans
Idioma:
En
Revista:
Daru
Ano de publicação:
2014
Tipo de documento:
Article